Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 14, Issue 3, 2009, Pages 176-179

  Desai, Harit ^a   Aronow, Wilbert S ^a   Tsai, Fausan S ^a   Ahn, Chul ^b   Lai, Hoang M ^a   Amin, Harshad ^a   Gandhi, Kaushang ^a   Frishman, William H ^a   Cohen, Martin ^a   Sorbera, Carmine ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cardiac resynchronization therapy; Cardioverter defibrillator shocks; Heart failure; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATOR; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SHOCK; SMOKING;

AGED; AGED, 80 AND OVER; CARDIAC PACING, ARTIFICIAL; CARDIOTONIC AGENTS; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; DIABETES COMPLICATIONS; DIGOXIN; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SMOKING; STROKE VOLUME; TACHYCARDIA, VENTRICULAR; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT;

EID: 69949095886     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248409340157     Document Type: Article

References (6)

1. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol. 2000 ; 36 (3). 766-772.
2. Mitchell LB, Powell JL, Gillis AM, Kehl V., Hallstrom AP, and the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 2003 ; 42 (1). 81-87.
3. Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol. 2005 ; 95 (4). 490-491.
4. Vyas AK, Guo H., Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter automatic Defibrillator Implantation trial (MADIT)-II. J Am Coll Cardiol. 2006 ; 47 (4). 769-773.
5. Lai HM, Aronow WS, Kruger A., et al. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators. Am J Cardiol. 2008 ; 102 (1). 77-78.
6. Aronow WS, Ahn C., Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. Am J Cardiol. 2000 ; 85 (11). 1382-1384.